newsfilter
← Latest News
PR Newswire·

Ribo and Madrigal Reach First Major Milestone in Advancing Novel siRNA Therapies for MASH

  • Suzhou Ribo Life Science Co., Ltd. (06938.HK) & its subsidiary Ribocure Pharmaceuticals AB (Ribo) announced the successful nomination of the first siRNA candidate drug under their partnership with Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL).
  • The milestone triggers immediate initiation of IND-enabling studies to support planned clinical trials.
  • The collaboration focuses on advancing RNA therapeutics for liver diseases, specifically targeting metabolic dysfunction-associated steatohepatitis (MASH).
  • Ribo co-CEO Li-Ming Gan highlighted the partnership's rapid progress driven by Madrigal's clinical expertise in MASH & Ribo's siRNA discovery & delivery capabilities.
  • The agreement covers multiple preclinical assets & aims to expand the therapeutic landscape for MASH.
  • Ribo is a clinical-stage R&D company utilizing RNA interference technology for nucleic acid drugs.
  • Ribocure, a subsidiary of Ribo, focuses on globalized development of oligonucleotide therapies & siRNA drugs.